Boedecker-Lips, Simone Cosima; Weinmann-Menke, Julia
Green Nephrology - What does this mean for dialysis procedures?DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT. Bd. 149. H. 14. 2024 S. 825-831
Gross, Sabrina; Bitzer, Michael; Bloedt, Susanne et al.
Guideline report of the S3 guideline "Diagnostics and therapy of hepatocellular carcinoma and biliary carcinomas"ZEITSCHRIFT FUR GASTROENTEROLOGIE. Bd. 62. H. 01. 2024 S. e162-e212
Marinoska, Tatjana; Triantafyllias, Konstantinos; Dreher, Matthias et al.
Handscupe: Ergonomic hand device for patients with rheumatic diseases - an explorative pilot studyPHYSIKALISCHE MEDIZIN REHABILITATIONSMEDIZIN KURORTMEDIZIN. Bd. 35. H. 03. 2024 S. 154-162
Moehler, Markus; Wyrwicz, Lucjan; Chen, Clara et al.
Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N plus C) vs (C)ONCOLOGY RESEARCH AND TREATMENT. Bd. 47. 2024 S. 65-65
Celsa, Ciro; Cabibbo, Giuseppe; Fulgenzi, Claudia et al.
Hepatic decompensation as an aetiology-dependent determinant of mortality in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumabJOURNAL OF HEPATOLOGY. Bd. 80. 2024 S. S51-S52
Celsa, Ciro; Cabibbo, Giuseppe; Fulgenzi, Claudia Angela Maria et al.
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatmentHEPATOLOGY. 2024
Schleicher, Eva Maria; Kaps, Leonard; Schattenberg, Jorn M. et al.
Higher scores in the Clinical Frailty Scale are associated with covert and overt hepatic encephalopathy in patients with cirrhosisDIGESTIVE AND LIVER DISEASE. Bd. 56. H. 6. 2024 S. 1046-1053
Lemmer, Dana; Ruck, Tobias; Schaenzer, Anne et al.
Idiopathic inflammatory myopathies: An interdisciplinary challengeZEITSCHRIFT FUR RHEUMATOLOGIE. Bd. 83. H. 6. 2024 S. 471-484
Finn, Richard S.; Breder, Valeriy; Vogel, Arndt et al.
IMBRAVE150: EXPLORATORY EFFICACY AND SAFETY RESULTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS (PTS) WITH MAIN TRUNK AND/OR CONTRALATERAL PORTAL VEIN INVASION (VP4) TREATED WITH ATEZOLIZUMAB (ATEZO) plus BEVACIZUMAB (BEV) VS SORAFENIB (SOR) IN A PH III STUDYGASTROENTEROLOGY. Bd. 166. H. 5. 2024 S. S1738-S1738
Leone, A. G.; Mai, A. S.; Fong, K. Y. et al.
Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroupsESMO OPEN. Bd. 9. H. 11. 2024